Skip to main content

Table 3 Prior treatments and clinical outcomes to axitinib and first subsequent therapy

From: Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

Patient ID Therapies prior to Axitinib Duration of axitinib treatment (mon) Best response to Axitinib Reason for discontinuation Interval from End of Axitinib Therapy to Start of Subsequent Therapy (weeks) Subsequent therapy 1 Best response
1 IL-2 plus IFN 18 PR PD 28 Sunitinib PR
2 IL-2 plus IFN 90 PR PD 1 Bevacizumab SD
3 IL-2 plus IFN 24 SD PD 41 Sunitinib Not evaluable
4 IL-2 6 PR PD 0 Pazopanib PD
5 IL-2 plus thalidomide, Sorafenib 41 PR PD 2 Sunitinib SD
6 IL-2/Bevacizumab 18 SD PD 3 Pazopanib SD
7 IL-2, sunitinib, IFN, sorafenib 8 SD PD 1 Bevacizumab PD
8 IL-2 plus IFN, BAY 43-9006, Sorafenib 31 PR Toxicity, RPLSa 10 Temserolimus SD
9 IFN,vinblastin plus thalidomide,IL-2, Gemcitabine plus Capecitabine, Sorafenib 53 PR Toxicity, MIb 7 Pazopanib SD
10 IFN, Sunitinib, Sorafinib 8 SD PD 35 Temserolimus SD
11 IFN, IL-2/thalidomide, IL-2/IFN, sunitinib, sorafenib 11 SD PD 2 Bevacizumab PD
12 ABX-EGF, CC-5013, 5FU/suramin, Sorafinib 4 SD PD 5 Sunitinib SD
13 Sunitinib 1 PD PD 0 Everolimus Not evaluable
14 Sunitinb 3 SD PD 1 Everolimus PD
15 Sunitinib 3 SD PD 0 Everolimus SD
16 Sorafenib 19 PR PD 2 Sunitinib PD
17 Sorafenibb 41 PR PD 2 Sunitinib SD
18 Temsirolimus 6 PR Toxicity 0 Pazopanib SD
19 None 29 PR PD 3 Everolimus SD
20 None 20 PR PD 2 Everolimus PD
21 None 2 CR Toxicity 0 Pazopanib PR
22 None 4 SD PD 32 Sunitinib SD
23 None 13 PR PD 2 Bevacizumab PD
24 None 6 SD PD 2 Pazopanib SD
25 None 6 PR PD 3 Sunitinib Not evaluable
  1. aReversible Posterior Leukoencephalopathy Syndrome
  2. bMyocardial Infarction